KENGREXAL® - Bioprojet
portfolio_page-template-default,single,single-portfolio_page,postid-2122,bridge-core-2.9.3,,qode_grid_1200,footer_responsive_adv,qode-child-theme-ver-1.0.0,qode-theme-ver-27.7,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.7.0,vc_responsive



CANGRELOR (powder for solution to be diluted for injection/perfusion)

Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease having undergone a percutaneous coronary intervention (PCI), who have not received an oral P2Y12 receptor inhibitor prior to the intervention and in whom the oral route for such a treatment is not feasible or desirable.

Useful links

European Commission

French Healthcare Authority